# To Demonstrate the Relative Bioequivalency of Generic Haloperidol Tablets Versus Haldol in Normal Volunteers

> **NCT00946491** · PHASE1 · COMPLETED · sponsor: **Sandoz** · enrollment: 30 (actual)

## Conditions studied

- Psychosis

## Interventions

- **DRUG:** Haloperidol 10 mg Tablets (Cord Laboratories)
- **DRUG:** Haldol 10 mg Tablets (McNeil Pharmaceuticals)

## Key facts

- **NCT ID:** NCT00946491
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1987-04
- **Primary completion:** 1987-05
- **Final completion:** 1987-05
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00946491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00946491, "To Demonstrate the Relative Bioequivalency of Generic Haloperidol Tablets Versus Haldol in Normal Volunteers". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00946491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*